# Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

> **NCT02920008** · PHASE3 · COMPLETED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 302 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** guadecitabine
- **DRUG:** Treatment Choice (TC)

## Key facts

- **NCT ID:** NCT02920008
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-16
- **Primary completion:** 2020-01-20
- **Final completion:** 2020-06-01
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02920008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02920008, "Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02920008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*